Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Gagandeep Brar, Sophie Wang, Anuradha Budhu, William D. Figg, Maggie Cam, Richard Finney, Elliot Levy, David E. Kleiner, Seth M. Steinberg, Xin Wei Wang, Bernadette Redd, Bradford J. Wood, Tim F. GretenCancer 2024 · DOI

TL;DR

This study investigated the efficacy and safety of combining immune checkpoint inhibitors (durvalumab and tremelimumab) with or without radiofrequency ablation (RFA) in patients with advanced biliary tract cancer (BTC). While both treatment arms showed similar, modest efficacy and a manageable safety profile, the addition of RFA did not significantly improve outcomes, suggesting that further research is needed to optimize treatment strategies for this challenging cancer.

What Problem Does This Paper Address?

Biliary tract cancer (BTC) is a rare but aggressive malignancy with a generally poor prognosis, especially in its advanced stages. Current standard treatments, such as gemcitabine and cisplatin combined with immune checkpoint inhibitors (ICIs), offer modest response rates and often short durations of benefit. This leaves a significant unmet need for more effective therapies. The researchers hypothesized that combining ICIs with interventional radiology (IR) techniques like RFA could enhance the anti-tumor immune response and improve outcomes for patients with advanced BTC, building on previous findings in hepatocellular carcinoma.

Methods

This was a prospective, two-cohort study. Patients with advanced BTC who had progressed on at least one prior line of systemic therapy were enrolled.

  • Cohort 1 (Durva/Treme): Received durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) intravenously every 4 weeks for four cycles, followed by monthly durvalumab alone until disease progression or unacceptable toxicity.
  • Cohort 2 (Durva/Treme + IR): Received the same ICI regimen as Cohort 1, with the addition of an interventional radiology (IR) procedure (specifically microwave ablation or radiofrequency ablation, though the abstract mentions RFA and the text mentions microwave ablation in prior work) on day 36.

Objective response was assessed using RECIST v1.1 criteria every 8 weeks. The primary endpoint was 6-month progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Correlative studies involved analyzing tumor mutation burden (TMB) and immune cell composition from biopsies.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • RFA Addition Doesn't Boost Efficacy: The most striking finding is that adding an IR procedure (RFA/microwave ablation) to the durvalumab and tremelimumab combination did not lead to a statistically significant improvement in PFS or OS compared to the ICI combination alone. This challenges the initial hypothesis that local tumor ablation would synergistically enhance systemic immunotherapy in this context.
  • Low TMB Predicts Poor Response: The study observed a generally low tumor mutation burden (TMB) across all samples. Low TMB is a known predictor of poor response to immunotherapy, which may partially explain the modest efficacy seen in this patient population.
  • Immune Microenvironment Similarities and Differences: While immune profiling revealed the presence of previously described immune subtypes in BTC, there were no significant differences in immune cell composition between pre- and post-treatment samples, nor between the two treatment arms. This suggests that the combination therapy, even with IR, did not dramatically alter the tumor immune microenvironment in a way that correlated with clinical response in this study.
  • BTC's Unique Immune Response: The authors speculate that the less promising response to ICIs in BTC compared to hepatocellular carcinoma (HCC), despite both originating in the liver, might be due to differences in tumorigenesis, distinct tumor immune responses, or the low mutational burden characteristic of BTC.
  • Refractory Disease Context: The study population consisted of patients with refractory disease who had already received prior therapy. This context of heavily pre-treated patients might limit the potential for any treatment to show significant efficacy, and future studies might benefit from evaluating these combinations in earlier lines of therapy.

Key Results

  • Enrollment: 25 patients with advanced BTC were enrolled. 17 received durvalumab and tremelimumab (Durva/Treme), and 6 received durvalumab, tremelimumab, plus an IR procedure (Durva/Treme + IR).
  • Efficacy:
    • Median PFS was 2.2 months (95% CI: 1.3-3.1) for Durva/Treme and 2.9 months (95% CI: 1.9-4.7) for Durva/Treme + IR (p=0.27).
  • Median OS was 5.1 months (95% CI: 2.5-6.9) for Durva/Treme and 5.8 months (95% CI: 2.9-40.1) for Durva/Treme + IR (p=0.31).
  • The disease control rate was modest at 30% for both cohorts combined.
  • One partial response was observed in the Durva/Treme arm.
  • Safety: Both treatment arms were well-tolerated with manageable adverse events (AEs). The majority of AEs were grade 1-2. There were no grade 4 AEs, and one grade 5 AE (myasthenia gravis) that resolved with treatment. The safety profiles were similar between the two cohorts.
  • TMB: TMB was low (<15 nonsynonymous mutations per Mb) across all samples.

Limitations and Future Work

  • Small Sample Size: The authors acknowledge that the small sample size and the heterogeneous nature of BTC (including different baseline disease statuses and primary tumor locations) limit the interpretation of the results.
  • Refractory Population: The study focused on patients with advanced, refractory BTC, which may not reflect the potential efficacy in earlier treatment settings.
  • Future Directions:
    • Larger, randomized studies are needed to fully characterize the efficacy of durvalumab and tremelimumab with or without IR in advanced BTC.
  • The authors suggest exploring the combination of ICIs, chemotherapy, and IR in future studies, given the known benefits of chemotherapy in combination with ICIs.
  • Further investigation into why BTC responds less favorably to ICIs compared to HCC is warranted, potentially exploring differences in tumorigenesis, immune response, or the impact of low mutational burden.

Summary updated

Abstract

Durva/Treme and Durva/Treme + IR showed similar efficacy. With a manageable safety profile. Larger studies are needed to fully characterize the efficacy of Durva/Treme ± IR in advanced BTC.
BibTeX
@inproceedings{monge2024combined,
  author = {Cecilia Monge and Changqing Xie and Yuta Myojin and Kelley Coffman and Donna Mabry Hrones and Gagandeep Brar and Sophie Wang and Anuradha Budhu and William D. Figg and Maggie Cam and Richard Finney and Elliot Levy and David E. Kleiner and Seth M. Steinberg and Xin Wei Wang and Bernadette Redd and Bradford J. Wood and Tim F. Greten},
  title = {{Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1002/cam4.6912},
}
Figure